Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 563-572

  Okita, Riki ^a   Yamaguchi, Yoshiyuki ^b   Ohara, Masahiro ^a   Hironaka, Katsuji ^a   Okawaki, Makoto ^a   Nagamine, Ichiro ^a   Ikeda, Takuhiro ^a   Emi, Akiko ^a   Hihara, Jun ^a   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Adoptive immunotherapy; Anti CD25 antibody; Basiliximab; Cancer immunotherapy; Regulatory T cell

Indexed keywords

BASILIXIMAB; FLUOROURACIL; GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3; CD2 ANTIGEN; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PRIMER DNA;

ABSENCE OF SIDE EFFECTS; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECTUM CANCER; CELL SURVIVAL; ESOPHAGUS TUMOR; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; NATURAL KILLER CELL; NEOPLASM; POLYMERASE CHAIN REACTION; RECTUM TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD2; ANTIGENS, CD4; CELL LINE, TUMOR; CELL SURVIVAL; DNA PRIMERS; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 64549145119     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000182     Document Type: Article

References (39)

1. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823-1841, 1982.
2. Smith KA: Interleukin-2. Curr Opin Immunol 4: 271-276, 1992.
3. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
4. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
5. Aruga A, Yamauchi K, Takasaki K, Furukawa T and Hanyu F: Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Int J Cancer 49: 19-24, 1991.
6. Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER and Bar MH: Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8: 1630-1636, 1990.
7. Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Shuimizu K, Minami K, Hihara J, Miyahara E and Toge T: Adoptive Immunotherapy of Cancer using Activated Autologous Lymphocytes -Current Status and New Strategies. Human Cell 16: 183-189, 2003.
8. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
9. Mescher MF: Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Immunol Rev 146: 177-210, 1995.
10. Yamaguchi Y, Ohta K, Kawabuchi Y, Ohshita A, Okita R, Okawaki M, Hironaka K, Matsuura K and Toge T: Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells. Anticancer Res 25: 2407-2415, 2005.
11. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P and Petersson M: Tumor-induced immune dysfunction. Cancer Immunol Immunother 48: 353-362, 1999.
12. Rosenberg SA: Shedding light on immunotherapy for cancer. N Engl J Med 350: 1461-1463, 2004.
13. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of single mechanism of self-tolerance causes various autoimmune disease. J Immunol 155: 1151-1164, 1995.
14. Yamaguchi T and Sakaguchi S: Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16: 115-123, 2006.
15. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA and Rosenberg SA: Cancer regression and autoimmunity induced by CTLA-4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377, 2003.
16. Belardelli F, Ferrantini M, Parmiani G, Schlom J and Garacil E: International meeting on cancer vaccines: How can we enhance efficacy of therapeutic vaccines ? Cancer Res 64: 6827-6830, 2004.
17. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005.
18. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E and Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633, 2005.
19. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA and Gomez-Navarro J: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23: 8968-8977, 2005.
20. Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, Castaigne JP, Moore R and Sweny P: Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 60: 748-756, 1995.
21. Kovarik J, Wolf P, Cisterne JM, Mourad G, Lebranchu Y, Lang P, Bourbigot B, Cantarovich D, Girault D, Gerbeau C, Schmidt AG and Soulillou JP: Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 64: 1701-1705, 1997.
22. + regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14: 1269-1273, 2005.
23. Katoh M: Expression of human SOX7 in normal tissues and tumors. Int J Mol Med 9: 363-368, 2002.
24. Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K and Toge T: Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 106: 1227-1236, 2006.
25. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
26. + regulatory T cells. J Exp Med 202: 885-891, 2005.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
28. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A and Dallaire BK: Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26: 66-73, 1999.
29. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
30. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gomez-Sanchez MA, Lage E, Manito N and Alonso-Pulpon L: A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 81: 1542-1548, 2006.
31. Lohse L, Nielsen J and Eriksen L: Long-term treatment of pigs with low doses of monoclonal antibodies against porcine CD4 and CD8 antigens. APMIS 114: 23-31, 2006.
32. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG and Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669, 2000.
33. Halak BK, Maguire HC and Lattime EC: Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59: 911-917, 1999.
34. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN and Hodge JW: The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 11: 4533-4544, 2005.
35. Orentas RJ, Kohler ME and Johnson BD: Suppression of anticancer immunity by regulatory T cells: Back to the future. Cancer Biol 16: 137-149, 2006.
36. + cells in vitro. Am J Transplant 5: 454-464, 2005.
37. Smithberg SR, Fogle JE, Mexas AM, Reckling SK, Lankford SM, Tompkins MB and Dean GA: In vivo depletion of CD4(+)CD25(+) regulatory T cells in cats. J Immunol Methods 329: 81-91, 2008.
38. + T regulatory cells. J Immunol 176: 3301-3305, 2006.
39. + T cells via IL-2-dependent mechanisms. Cell Immunol 235: 56-64, 2005.